|
1
|
Bielack SS, Kempf-Bielack B, Delling G, et
al: Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
4
|
Ferrari S, Smeland S, Mercuri M, et al:
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose
methotrexate, cisplatin, and doxorubicin for patients with
localized osteosarcoma of the extremity: a joint study by the
Italian and Scandinavian Sarcoma Groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lewis IJ, Nooij MA and Whelan J:
Improvement in histologic response but not survival in osteosarcoma
patients treated with intensified chemotherapy: a randomized phase
III trial of the European Osteosarcoma Intergroup. J Natl Cancer
Inst. 99:112–128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meyers PA, Schwartz CL, Krailo MD, et al;
Children’s Oncology Group. Osteosarcoma: the addition of muramyl
tripeptide to chemotherapy improves overall survival - a report
from the Children’s Oncology Group. J Clin Oncol. 26:633–638. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anninga JK, Gelderblom H, Fiocco M, et al:
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we
stand? Eur J Canc. 47:2431–2445. 2011. View Article : Google Scholar
|
|
8
|
Le Deley MC, Guinebretière JM, Gentet JC,
et al; Société Française d’Oncologie Péediatrique (SFOP). SFOP
OS94: a randomised trial comparing preoperative high-dose
methotrexate plus doxorubicin to high-dose methotrexate plus
etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer.
43:752–761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patiño-Garcia A, Zalacaín M, Marrodán L,
San-Julián M and Sierrasesúmaga L: Methotrexate in pediatric
osteosarcoma: response and toxicity in relation to genetic
polymorphisms and dihydrofolate reductase and reduced folate
carrier 1 expression. J Pediatr. 154:688–693. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Delepine N, Delepine G, Jasmin C, Desbois
JC, Cornille H and Mathé G: Importance of age and methotrexate
dosage: prognosis in children and young adults with high-grade
osteosarcomas. Biomed Pharmacother. 42:257–262. 1988.PubMed/NCBI
|
|
11
|
Wang JJ and Li GJ: Relationship between
RFC gene expression and intracellular drug concentration in
methotrexate-resistant osteosarcoma cells. Genet Mol Res.
13:5313–5321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Laverdière C, Chiasson S, Costea I,
Moghrabi A and Krajinovic M: Polymorphism G80A in the reduced
folate carrier gene and its relationship to methotrexate plasma
levels and outcome of childhood acute lymphoblastic leukemia.
Blood. 100:3832–3834. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hattinger CM, Reverter-Branchat G,
Remondini D, et al: Genomic imbalances associated with methotrexate
resistance in human osteosarcoma cell lines detected by comparative
genomic hybridization-based techniques. Eur J Cell Biol.
82:483–493. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaufman Y, Drori S, Cole PD, et al:
Reduced folate carrier mutations are not the mechanism underlying
methotrexate resistance in childhood acute lymphoblastic leukemia.
Cancer. 100:773–782. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Serra M, Reverter-Branchat G, Maurici D,
et al: Analysis of dihydrofolate reductase and reduced folate
carrier gene status in relation to methotrexate resistance in
osteosarcoma cells. Ann Oncol. 15:151–160. 2004. View Article : Google Scholar
|
|
16
|
Biedler JL and Riehm H: Cellular
resistance to actinomycin D in Chinese hamster cells in vitro:
Cross-resistance, radioautographic and cytogenetic studies. Cancer
Res. 30:1174–1184. 1970.PubMed/NCBI
|
|
17
|
Stein U, Walther W and Wunderlich V: Point
mutations in the mdrl1 promoter of human osteosarcomas are
associated with in vitro responsiveness to multidrug resistance
relevant drugs. Eur J Cancer. 30A:1541–1545. 1994. View Article : Google Scholar
|
|
18
|
Fan K, Fan D, Cheng LF and Li C:
Expression of multidrug resistance-related markers in gastric
cancer. Anticancer Res. 20:4809–4814. 2000.
|
|
19
|
Schwartz CL, Gorlick R, Teot L, et al;
Children’s Oncology Group. Multiple drug resistance in osteogenic
sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol.
25:2057–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Benderra Z, Faussat AM, Sayada L, et al:
Breast cancer resistance protein and P-glycoprotein in 149 adult
acute myeloid leukemias. Clin Cancer Res. 10:7896–7902. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim DH, Lee NY, Sung WJ, et al: Multidrug
resistance as a potential prognostic indicator in acute myeloid
leukemia with normal karyotypes. Acta Haematol. 114:78–83. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marsh S, Paul J, King CR, Gifford G,
McLeod HL and Brown R: Pharmacogenetic assessment of toxicity and
outcome after platinum plus taxane chemotherapy in ovarian cancer:
the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol.
25:4528–4535. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Müller PJ, Dally H, Klappenecker CN, et
al: Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible
impact on chemotherapy outcome of lung cancer patients. Int J
Cancer. 124:1669–1674. 2009. View Article : Google Scholar
|
|
24
|
Sun N, Sun X, Chen B, et al: MRP2 and
GSTP1 polymorphisms and chemotherapy response in advanced non-small
cell lung cancer. Cancer Chemother Pharmacol. 65:437–446. 2010.
View Article : Google Scholar
|
|
25
|
Baldini N, Scotlandi K, Serra M, et al:
P-glycoprotein expression in osteosarcoma: a basis for risk-adapted
adjuvant chemotherapy. J Orthop Res. 17:629–632. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith MA, Merry S, Smith JG and Kaye SB:
Clinically relevant concentrations of verapamil do not enhance the
sensitivity of human bone marrow CFU-GM to adriamycin and VP16. Br
J Cancer. 57:576–578. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shudo N, Mizoguchi T, Kiyosue T, Arita M,
Yoshimura A, Seto K, Sakoda R and Akiyama S: Two pyridine analogues
with more effective ability to reverse multidrug resistance and
with lower calcium channel blocking activity than their
dihydropyridine counterparts. Cancer Res. 50:3055–3061.
1990.PubMed/NCBI
|
|
28
|
Mahmood M, Mustafa T, Xu Y, Nima Z,
Kannarpady G, Bourdo S, Casciano D and Biris AS: Calcium-channel
blocking and nanoparticles-based drug delivery for treatment of
drug-resistant human cancers. Ther Deliv. 5:763–780. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Othman RT, Kimishi I, Bradshaw TD, Storer
LC, Korshunov A, Pfister SM, Grundy RG, Kerr ID and Coyle B:
Overcoming multiple drug resistance mechanisms in medulloblastoma.
Acta Neuropathol Commun. 2:572014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zu Y, Yang Z, Tang S, Han Y and Ma J:
Effects of P-glycoprotein and its inhibitors on apoptosis in K562
cells. Molecules. 19:13061–13075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim SS, Seong S and Kim SY: Synergistic
effect of ginsenoside Rg3 with verapamil on the modulation of
multidrug resistance in human acute myeloid leukemia cells. Oncol
Lett. 7:1265–1269. 2014.PubMed/NCBI
|
